InnoCare Pharma Ltd. A (688428)
Shanghai Stock Exchange · China · prices in CNY · close of 27 Oct 2026
Key indicators
| Last close | CNY 25.16 |
|---|---|
| 52-week range | 19.36 – 35.00 |
| Return, 1 month / 3 months | −15.7% / −9.3% |
| Return, 1 year / 3 years | +9.2% / +150.6% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 53.1% |
| Worst drawdown (1 year) | -35.0% |
| Average daily value traded | 363.55M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
InnoCare Pharma is a biopharmaceutical company based in Beijing that discovers, develops and commercialises medicines for cancer and autoimmune diseases. Its main marketed product is a small-molecule drug for certain blood cancers, and its pipeline includes treatments being studied for lymphoma, autoimmune conditions and other diseases. The company serves patients and physicians through hospitals and healthcare providers in China, and it also conducts clinical development work aimed at broader markets.
The shares are listed on the Shanghai Stock Exchange in China under the code 688428, and the price on this page is in Chinese yuan (CNY). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
InnoCare Pharma Ltd. A (688428) trades on the Shanghai Stock Exchange in China. It last closed at CNY 25.16 on 27 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 348 of 2,280 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 9.2% and over the last three months it fell 9.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | -3.2% | ||
| From 52-week high | -24.7% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -9.3% | ||
| 6-month return | -9.9% | ||
| 12-month return, skipping the last month | 29.7% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 53.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.0% | ||
| Liquidity | 76 · Strong | Trades actively. | |
| Average daily value traded | 363.55M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −5.8% |
|---|---|
| 1 month | −15.7% |
| 3 months | −9.3% |
| 6 months | −9.9% |
| 1 year | +9.2% |
| 3 years | +150.6% |
| 5 years | – |
Signals
| 50-day / 200-day average | 28.84 / 26.00 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.77 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.